Results 241 to 250 of about 499,108 (302)

Substituent‐Based Modulation of Self‐Assembly and Immunogenicity of Amphipathic Peptides

Advanced Science, EarlyView.
This study systematically investigates how positional and subtle changes, such as substituents on the phenyl ring attached to short amphipathic peptides, influence their self‐assembly, fibril morphology, and immunogenic responses. ABSTRACT Self‐assembled peptide‐based biomaterials provide versatile platforms for biomedical uses, featuring customizable ...
Anirban Das, Ushasi Pramanik, Elise M. Brown, Chih‐Yun Liu, Huan Gong, Jonathan Fascetti, Mark Gibson, Samuel Stealey, Silviya P. Zustiak, Cory Berkland, Piyoosh Sharma, Meredith E. Jackrel, Mark A. White, Jai S. Rudra   +13 more
wiley   +1 more source

Allosteric ligand-driven smart nanoconjugates for mutation-selective EGFR targeting: A precision approach to overcoming tyrosine kinase inhibitor resistance. [PDF]

Bioimpacts
Singh D, Kumar A, Sharma VV.
europepmc   +1 more source

Chaperone‐Mediated Autophagic Degradation of USP9X in Macrophages Exacerbates Postmyocardial Infarction Inflammation and Cardiac Dysfunction

Advanced Science, EarlyView.
This study demonstrates that inflammatory stimuli induce the acetylation‐triggered, chaperone‐mediated autophagic degradation of ubiquitin‐specific peptidase 9 X‐linked (USP9X) in macrophages. USP9X acts as a macrophage “inflammation switch” after myocardial infarction (MI). USP9X loss destabilizes tumor necrosis factor receptor‐associated factor (TRAF)
Biqing Wang, Xiangheng Cai, Mengqi Li, Xue Liu, Junhui Xue, Ye Liu, Ding Ai, Xinyang Hu   +7 more
wiley   +1 more source

Retraction Note: Rechallenge therapy versus tyrosine kinase inhibitor (TKI) for advanced metastatic colorectal cancer: a retrospective study. [PDF]

Sci Rep
Liu C, Chen J, Liu Y.
europepmc   +1 more source

Targeting PRKCN, an Essential Driver Orchestrating mTOR‐IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma

Advanced Science, EarlyView.
Constitutive PRKCN expression is driven by super‐enhancers and modulated by NF‐κB signaling in multiple myeloma (MM). PRKCN activates mTORC1/2‐IRF4 signaling axis and favors tumor cell growth independently of its kinase activity. IRF4 reciprocally promotes PRKCN transcription, creating a feed‐forward loop.
Koukou Tang, Dongpeng Jiang, Peng Ke, Xiaosen Bian, Lili Zhang, Ying Zhang, Tingting Zhu, Weiwei Qu, Wenhui Qi, Yang Xu, Chengcheng Fu, Depei Wu, Jianhong Chu   +12 more
wiley   +1 more source

Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer. [PDF]

Clin Cancer Res
Gonzalez-Ericsson PI, Unni N, Jhaveri K, Stringer-Reasor E, Liu Q, Wang Y, Sanchez V, Garcia G, Sanders ME, Lehmann BD, Balko JM, Park B, Rexer BN, Mayer IA, Arteaga CL.   +14 more
europepmc   +1 more source

254 Tyrosine kinase inhibitors

European Journal of Cancer Supplements, 2009
openaire   +1 more source

The spleen tyrosine kinase inhibitor entospletinib resolves inflammation to promote repair following acute kidney injury. [PDF]

JCI Insight
Elias EE, Lau A, Belay SG, Derakhshani A, Andonegui G, Jenne CN, Dufour A, Bracey NA, Chun J, Muruve DA.   +9 more
europepmc   +1 more source

EMP3 is upregulated upon epithelial-mesenchymal transition and contributes to EGFR-tyrosine kinase inhibitor resistance in lung adenocarcinoma. [PDF]

Eur J Med Res
Wang C, Xiong M, Zhu Y, Li K, Ni J.
europepmc   +1 more source

Meta-Analysis Exploring Tyrosine Kinase Inhibitor-Induced Weight Gain in Oncogene-Addicted NSCLC. [PDF]

JTO Clin Res Rep
Scaglione IM, Avancini A, Eccher S, Borsati A, Pasqualin L, La Cava G, Trestini I, Tregnago D, Sposito M, Insolda J, Giannarelli D, Milella M, Pilotto S, Belluomini L.   +13 more
europepmc   +1 more source